These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 26555315)

  • 1. Corticotropin-releasing factor receptor-1 antagonism mitigates beta amyloid pathology and cognitive and synaptic deficits in a mouse model of Alzheimer's disease.
    Zhang C; Kuo CC; Moghadam SH; Monte L; Campbell SN; Rice KC; Sawchenko PE; Masliah E; Rissman RA
    Alzheimers Dement; 2016 May; 12(5):527-37. PubMed ID: 26555315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of CRFR1 Ablation on Amyloid-β Production and Accumulation in a Mouse Model of Alzheimer's Disease.
    Campbell SN; Zhang C; Roe AD; Lee N; Lao KU; Monte L; Donohue MC; Rissman RA
    J Alzheimers Dis; 2015; 45(4):1175-84. PubMed ID: 25697705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corticotropin-Releasing Factor Receptor-1 Antagonism Reduces Oxidative Damage in an Alzheimer’s Disease Transgenic Mouse Model.
    Zhang C; Kuo CC; Moghadam SH; Monte L; Rice KC; Rissman RA
    J Alzheimers Dis; 2015; 45(2):639-50. PubMed ID: 25649650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corticotrophin releasing factor accelerates neuropathology and cognitive decline in a mouse model of Alzheimer's disease.
    Dong H; Murphy KM; Meng L; Montalvo-Ortiz J; Zeng Z; Kolber BJ; Zhang S; Muglia LJ; Csernansky JG
    J Alzheimers Dis; 2012; 28(3):579-92. PubMed ID: 22045495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corticotropin-releasing factor receptor-1 modulates biomarkers of DNA oxidation in Alzheimer's disease mice.
    Zhang C; Rissman RA
    PLoS One; 2017; 12(7):e0181367. PubMed ID: 28750017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corticotropin-releasing factor receptor 1 activation during exposure to novelty stress protects against Alzheimer's disease-like cognitive decline in AβPP/PS1 mice.
    Scullion GA; Hewitt KN; Pardon MC
    J Alzheimers Dis; 2013; 34(3):781-93. PubMed ID: 23302658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased tau phosphorylation and aggregation in the hippocampus of mice overexpressing corticotropin-releasing factor.
    Campbell SN; Zhang C; Monte L; Roe AD; Rice KC; Taché Y; Masliah E; Rissman RA
    J Alzheimers Dis; 2015; 43(3):967-76. PubMed ID: 25125464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RAPGEF2 mediates oligomeric Aβ-induced synaptic loss and cognitive dysfunction in the 3xTg-AD mouse model of Alzheimer's disease.
    Jang YN; Jang H; Kim GH; Noh JE; Chang KA; Lee KJ
    Neuropathol Appl Neurobiol; 2021 Aug; 47(5):625-639. PubMed ID: 33345400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of corticotrophin-releasing factor receptor 1 antagonists on amyloid-β and behavior in Tg2576 mice.
    Dong H; Wang S; Zeng Z; Li F; Montalvo-Ortiz J; Tucker C; Akhtar S; Shi J; Meltzer HY; Rice KC; Csernansky JG
    Psychopharmacology (Berl); 2014 Dec; 231(24):4711-22. PubMed ID: 24862368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer's disease.
    Sakakibara Y; Sekiya M; Saito T; Saido TC; Iijima KM
    BMC Neurosci; 2019 Mar; 20(1):13. PubMed ID: 30894120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corticotropin-releasing factor overexpression gives rise to sex differences in Alzheimer's disease-related signaling.
    Bangasser DA; Dong H; Carroll J; Plona Z; Ding H; Rodriguez L; McKennan C; Csernansky JG; Seeholzer SH; Valentino RJ
    Mol Psychiatry; 2017 Aug; 22(8):1126-1133. PubMed ID: 27752081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins.
    Pham E; Crews L; Ubhi K; Hansen L; Adame A; Cartier A; Salmon D; Galasko D; Michael S; Savas JN; Yates JR; Glabe C; Masliah E
    FEBS J; 2010 Jul; 277(14):3051-67. PubMed ID: 20573181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The flavonoid baicalein rescues synaptic plasticity and memory deficits in a mouse model of Alzheimer's disease.
    Gu XH; Xu LJ; Liu ZQ; Wei B; Yang YJ; Xu GG; Yin XP; Wang W
    Behav Brain Res; 2016 Sep; 311():309-321. PubMed ID: 27233830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central CRF system perturbation in an Alzheimer's disease knockin mouse model.
    Guo Q; Zheng H; Justice NJ
    Neurobiol Aging; 2012 Nov; 33(11):2678-91. PubMed ID: 22336193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corticosterone and related receptor expression are associated with increased beta-amyloid plaques in isolated Tg2576 mice.
    Dong H; Yuede CM; Yoo HS; Martin MV; Deal C; Mace AG; Csernansky JG
    Neuroscience; 2008 Jul; 155(1):154-63. PubMed ID: 18571864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tripchlorolide improves cognitive deficits by reducing amyloid β and upregulating synapse-related proteins in a transgenic model of Alzheimer's Disease.
    Zeng Y; Zhang J; Zhu Y; Zhang J; Shen H; Lu J; Pan X; Lin N; Dai X; Zhou M; Chen X
    J Neurochem; 2015 Apr; 133(1):38-52. PubMed ID: 25661995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification.
    Izzo NJ; Yuede CM; LaBarbera KM; Limegrover CS; Rehak C; Yurko R; Waybright L; Look G; Rishton G; Safferstein H; Hamby ME; Williams C; Sadlek K; Edwards HM; Davis CS; Grundman M; Schneider LS; DeKosky ST; Chelsky D; Pike I; Henstridge C; Blennow K; Zetterberg H; LeVine H; Spires-Jones TL; Cirrito JR; Catalano SM
    Alzheimers Dement; 2021 Aug; 17(8):1365-1382. PubMed ID: 33559354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disrupted Maturation of Prefrontal Layer 5 Neuronal Circuits in an Alzheimer's Mouse Model of Amyloid Deposition.
    Chen C; Wei J; Ma X; Xia B; Shakir N; Zhang JK; Zhang L; Cui Y; Ferguson D; Qiu S; Bai F
    Neurosci Bull; 2023 Jun; 39(6):881-892. PubMed ID: 36152121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Theranostic F-SLOH mitigates Alzheimer's disease pathology involving TFEB and ameliorates cognitive functions in Alzheimer's disease models.
    Iyaswamy A; Wang X; Krishnamoorthi S; Kaliamoorthy V; Sreenivasmurthy SG; Kumar Durairajan SS; Song JX; Tong BC; Zhu Z; Su CF; Liu J; Cheung KH; Lu JH; Tan JQ; Li HW; Wong MS; Li M
    Redox Biol; 2022 May; 51():102280. PubMed ID: 35286997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enriched endogenous n-3 polyunsaturated fatty acids alleviate cognitive and behavioral deficits in a mice model of Alzheimer's disease.
    Wu K; Gao X; Shi B; Chen S; Zhou X; Li Z; Gan Y; Cui L; Kang JX; Li W; Huang R
    Neuroscience; 2016 Oct; 333():345-55. PubMed ID: 27474225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.